Harrow, Inc. (NASDAQ:HROW) Receives $71.43 Average PT from Analysts

Shares of Harrow, Inc. (NASDAQ:HROW) have received a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $71.4286.

A number of research analysts have issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research report on Thursday, January 22nd. Cantor Fitzgerald restated an “overweight” rating and issued a $94.00 price objective on shares of Harrow in a report on Tuesday, November 11th. LADENBURG THALM/SH SH lifted their target price on shares of Harrow from $64.00 to $66.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. HC Wainwright increased their price target on Harrow from $64.00 to $69.00 and gave the company a “buy” rating in a research note on Wednesday, November 12th. Finally, Zacks Research cut Harrow from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 2nd.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of HROW. Virtu Financial LLC bought a new stake in Harrow in the fourth quarter valued at approximately $702,000. Invesco Ltd. grew its holdings in shares of Harrow by 35.7% in the 4th quarter. Invesco Ltd. now owns 145,406 shares of the company’s stock valued at $7,125,000 after buying an additional 38,264 shares during the period. Occudo Quantitative Strategies LP bought a new stake in shares of Harrow in the 4th quarter valued at $801,000. Cetera Investment Advisers raised its stake in Harrow by 2.6% during the 4th quarter. Cetera Investment Advisers now owns 23,256 shares of the company’s stock worth $1,140,000 after buying an additional 597 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Harrow by 4.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 25,412 shares of the company’s stock worth $1,246,000 after acquiring an additional 1,161 shares in the last quarter. Institutional investors own 72.76% of the company’s stock.

Harrow Trading Down 0.9%

Shares of HROW opened at $51.55 on Tuesday. The company has a quick ratio of 2.52, a current ratio of 2.72 and a debt-to-equity ratio of 5.21. Harrow has a 12-month low of $20.85 and a 12-month high of $54.85. The firm has a market capitalization of $1.91 billion, a PE ratio of -515.45 and a beta of 0.07. The stock’s fifty day simple moving average is $47.85 and its 200-day simple moving average is $43.17.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.